Analysts Set Korro Bio, Inc. (NASDAQ:KRRO) Price Target at $144.00

Korro Bio, Inc. (NASDAQ:KRRO) has been given a consensus rating of “Buy” by the seven brokerages that are covering the company, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $144.00.

Several equities analysts have weighed in on the company. Oppenheimer initiated coverage on Korro Bio in a research report on Friday, January 10th. They issued an “outperform” rating and a $155.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $115.00 price objective on shares of Korro Bio in a research report on Friday, November 22nd. Finally, William Blair reissued an “outperform” rating on shares of Korro Bio in a research report on Wednesday, November 13th.

Korro Bio Stock Down 3.9 %

NASDAQ KRRO opened at $24.62 on Friday. The stock has a 50-day moving average of $35.38 and a two-hundred day moving average of $43.81. Korro Bio has a 1-year low of $24.60 and a 1-year high of $98.00.

Institutional Investors Weigh In On Korro Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quest Partners LLC raised its position in Korro Bio by 172.1% in the third quarter. Quest Partners LLC now owns 1,777 shares of the company’s stock worth $59,000 after acquiring an additional 1,124 shares in the last quarter. Brown Brothers Harriman & Co. raised its position in Korro Bio by 251.0% in the third quarter. Brown Brothers Harriman & Co. now owns 2,854 shares of the company’s stock worth $95,000 after acquiring an additional 2,041 shares in the last quarter. BNP Paribas Financial Markets raised its position in Korro Bio by 1,018.2% in the third quarter. BNP Paribas Financial Markets now owns 4,909 shares of the company’s stock worth $164,000 after acquiring an additional 4,470 shares in the last quarter. MetLife Investment Management LLC raised its position in Korro Bio by 129.0% in the third quarter. MetLife Investment Management LLC now owns 3,639 shares of the company’s stock worth $122,000 after acquiring an additional 2,050 shares in the last quarter. Finally, State Street Corp raised its position in Korro Bio by 18.9% in the third quarter. State Street Corp now owns 118,765 shares of the company’s stock worth $3,969,000 after acquiring an additional 18,877 shares in the last quarter. Hedge funds and other institutional investors own 13.18% of the company’s stock.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).